Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;194(6):509-519.
doi: 10.1007/s00066-018-1287-1. Epub 2018 Mar 2.

Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies

Affiliations
Review

Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies

Michael Rückert et al. Strahlenther Onkol. 2018 Jun.

Abstract

Background: Radiotherapy (RT) has been known for decades as a local treatment modality for malign and benign disease. In order to efficiently exploit the therapeutic potential of RT, an understanding of the immune modulatory properties of ionizing radiation is mandatory. These should be used for improvement of radioimmunotherapies for cancer in particular.

Methods: We here summarize the latest research and review articles about immune modulatory properties of RT, with focus on radiation dose and on combination of RT with selected immunotherapies. Based on the knowledge of the manifold immune mechanisms that are triggered by RT, thought-provoking impulse for multimodal radioimmunotherapies is provided.

Results: It has become obvious that ionizing radiation induces various forms of cell death and associated processes via DNA damage initiation and triggering of cellular stress responses. Immunogenic cell death (ICD) is of special interest since it activates the immune system via release of danger signals and via direct activation of immune cells. While RT with higher single doses in particular induces ICD, RT with a lower dose is mainly responsible for immune cell recruitment and for attenuation of an existing inflammation. The counteracting immunosuppression emanating from tumor cells can be overcome by combining RT with selected immunotherapies such as immune checkpoint inhibition, TGF-β inhibitors, and boosting of immunity with vaccination.

Conclusion: In order to exploit the full power of RT and thereby develop efficient radioimmunotherapies, the dose per fraction used in RT protocols, the fractionation, the quality, and the quantity of certain immunotherapies need to be qualitatively and chronologically well-matched to the individual immune status of the patient.

Keywords: Immune checkpoint inhibition; Immunogenic cell death; Inflammation; Ionising radiation; Vaccination.

PubMed Disclaimer

References

    1. Front Immunol. 2015 Oct 08;6:505 - PubMed
    1. J Immunother Cancer. 2016 Sep 20;4:51 - PubMed
    1. Immunol Rev. 2017 Nov;280(1):231-248 - PubMed
    1. Phys Med Biol. 2016 Jan 21;61(2):515-26 - PubMed
    1. Strahlenther Onkol. 2015 Dec;191(12):979-84 - PubMed

MeSH terms

LinkOut - more resources